Arbutus Biopharma Corp Expects Loss of 8 Cents per Share and 27.1% Decline in Quarterly Revenue in 2024

Summary

Arbutus Biopharma Corp expects to report a loss of 8 cents per share for the period ending December 31, 2024, with quarterly revenue dropping by 27.1% to a total of $1.563 million. Despite these projections, analysts maintain a ‘buy’ rating with a 12-month median target price of $5.00, which is higher than the last closing price of $3.42. Previous financial results have been mixed, with some estimates being met and others not.

Impact Analysis

This is a company-level event impacting Arbutus Biopharma Corp. The projected financial results may lead to volatility in the company’s stock price, as investors react to the expected loss and revenue decline. Despite this, the maintained ‘buy’ rating and higher target price suggest that analysts see potential for recovery or growth, possibly due to positive prospects in the company’s pipeline or strategic initiatives. The event might present a buying opportunity for investors who trust the analyst’s outlook, especially if the stock reacts negatively to the upcoming earnings release. However, risks include continued underperformance or market skepticism regarding future growth prospects.